1.1 Certolizumab pegol is recommended as an option for the treatment of people with rheumatoid arthritis only if:
certolizumab pegol is used as described for other tumour necrosis factor (TNF) inhibitor treatments in 'Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis' (NICE technology appraisal guidance 130) and
the manufacturer provides the first 12 weeks of certolizumab pegol (10 pre-loaded 200-mg syringes) free of charge to all patients starting treatment.
1.2 When using the DAS28 (as set out in NICE technology appraisal guidance 130), healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties that could affect a person's responses to the DAS28 and make any adjustments they consider appropriate.